bioMérieux S.A. (BIM.PA)

99.25 +0.15 (+0.15%) 收市：05:35PM CEST

bioMérieux S.A.

376 Chemin De l’Orme
Marcy-l'Étoile 69280
France
33 4 78 87 20 00
https://www.biomerieux.com

版塊: Healthcare
行業: Diagnostics & Research
全職員工: 13,409

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Pierre Boulud	Chief Executive Officer	1.35M	無	1971
Mr. Guillaume Bouhours	Executive VP of Purchasing and Information Systems & CFO	無	無	1976
Sylvain Morgeau	Investor Relations	無	無	無
Ms. Audrey Dauvet	Executive Vice President of Legal, Corporate Integrity & Public Affairs	無	無	1974
Ms. Valerie Leylde	Executive Vice President of Human Resources, Communications & CSR	無	無	無
Mr. Pierre Charbonnier	Executive Vice President of Global Quality, Manufacturing & Supply Chain	無	無	無
Mr. Yasha Mitrotti	Executive Vice President of Industrial Applications	無	無	無
Mr. Frederic Beseme	Head of CSR	21.99k	無	1956
Jennifer Zinn	Executive Vice President of Clinical Operations	無	無	無
Charles K. Cooper	Executive VP & Chief Medical Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

公司管治

截至 2024年5月1日 止，bioMérieux S.A. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：5；董事會：8；股東權利：8；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。